Namodenoson

A patient treated with Namodenoson in Can-Fite's Phase II Liver Cancer Study has shown an 8-year overall survival with complete response. Namodenoson, with Orphan Drug and Fast Track status, is now in a pivotal Phase III study for advanced HCC, aiming to prolong survival. The drug's unique action against tumor cells while protecting normal liver cells underpins the trial's rationale.

Can-Fite BioPharma announced a patient treated with Namodenoson in a Phase II Liver Cancer Study achieved 8 years of overall survival with complete response.

Switch Market flag for country-specific data. Right-click for chart options. Use arrows to navigate symbols.

Can-Fite BioPharma announces first patient dosed in Phase IIa trial for advanced pancreatic adenocarcinoma, evaluating Namodenoson's safety and efficacy. Namodenoson, an A3 adenosine receptor agonist, has received Orphan Drug Designation from the US FDA.

Can-Fite BioPharma announces first patient dosing in Phase IIa pancreatic cancer trial, evaluating Namodenoson's safety and clinical activity.

Can-Fite BioPharma announced the acceptance of Namodenoson's patent in Australia, valid until 2040, covering its use in treating obesity. Namodenoson, an oral drug with a favorable safety profile, is under development for MASH, advanced liver cancer, and pancreatic cancer. It reduces fat levels and body weight, with a Phase IIa study showing a 2.3% weight loss in MASH patients.

October 2024 saw significant FDA actions in oncology, including priority reviews for T-DXd in HER2-low/ultra-low breast cancer, acalabrutinib for frontline mantle cell lymphoma, and approvals for nivolumab plus chemotherapy in operable NSCLC, Cologuard Plus for CRC screening, and zolbetuximab for HER2-negative gastric cancer. Other notable actions included fast track designations, orphan drug designations, and expanded approvals for various cancer treatments.

Can-Fite BioPharma Ltd. (CANF) develops oral therapeutics targeting A3AR for cancer, liver, and inflammatory diseases. Key drugs include Piclidenoson (Phase III psoriasis) and Namodenoson (Phase III HCC, Phase IIb NASH). Based in Israel, the company leverages partnerships to advance drug development.